Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Scientific Reports

Topics

Medicine

Cancer Oncology

Immunology

Pathology

Internal Medicine

Show all topics

DOI

10.1038/s41598-024-79130-7

License

CC-BY-NC-ND

Other Formats

PDF